These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33751838)

  • 21. Influence of Breed Size, Age, Fecal Quality, and Enteropathogen Shedding on Fecal Calprotectin and Immunoglobulin A Concentrations in Puppies During the Weaning Period.
    Grellet A; Heilmann RM; Polack B; Feugier A; Boucraut-Baralon C; Grandjean D; Grützner N; Suchodolski JS; Steiner JM; Chastant-Maillard S
    J Vet Intern Med; 2016 Jul; 30(4):1056-64. PubMed ID: 27279352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of serum calprotectin (S100A8/A9) concentrations and idiopathic hyperlipidemia in Miniature Schnauzers.
    Heilmann RM; Xenoulis PG; Müller K; Stavroulaki EM; Suchodolski JS; Steiner JM
    J Vet Intern Med; 2019 Mar; 33(2):578-587. PubMed ID: 30788872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis.
    de Seny D; Fillet M; Ribbens C; Marée R; Meuwis MA; Lutteri L; Chapelle JP; Wehenkel L; Louis E; Merville MP; Malaise M
    Clin Chem; 2008 Jun; 54(6):1066-75. PubMed ID: 18436720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic performance of the urinary canine calgranulins in dogs with lower urinary or urogenital tract carcinoma.
    Heilmann RM; McNiel EA; Grützner N; Lanerie DJ; Suchodolski JS; Steiner JM
    BMC Vet Res; 2017 Apr; 13(1):112. PubMed ID: 28431528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of fecal S100A12 as a novel non-invasive diagnostic biomarker for pediatric inflammatory bowel disease: a systematic review and meta-analysis.
    Witarto BS; Visuddho V; Witarto AP; Sampurna MTA; Irzaldy A
    J Pediatr (Rio J); 2023; 99(5):432-442. PubMed ID: 37094752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preanalytical validation of an in-house radioimmunoassay for measuring calprotectin in feline specimens.
    Heilmann RM; Grützner N; Handl S; Suchodolski JS; Steiner JM
    Vet Clin Pathol; 2018 Mar; 47(1):100-107. PubMed ID: 29377247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
    J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease.
    Leach ST; Yang Z; Messina I; Song C; Geczy CL; Cunningham AM; Day AS
    Scand J Gastroenterol; 2007 Nov; 42(11):1321-31. PubMed ID: 17852869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease.
    de Jong NS; Leach ST; Day AS
    Inflamm Bowel Dis; 2006 Jul; 12(7):566-72. PubMed ID: 16804393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12.
    Däbritz J; Langhorst J; Lügering A; Heidemann J; Mohr M; Wittkowski H; Krummenerl T; Foell D
    Inflamm Bowel Dis; 2013 May; 19(6):1130-8. PubMed ID: 23377171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
    Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
    Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal calprotectin concentrations in adult dogs with chronic diarrhea.
    Grellet A; Heilmann RM; Lecoindre P; Feugier A; Day MJ; Peeters D; Freiche V; Hernandez J; Grandjean D; Suchodolski JS; Steiner JM
    Am J Vet Res; 2013 May; 74(5):706-11. PubMed ID: 23627383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of urinary canine S100A8/A9 and S100A12 concentrations as candidate biomarkers of lower urinary tract neoplasia in dogs.
    Heilmann RM; Wright ZM; Lanerie DJ; Suchodolski JS; Steiner JM
    J Vet Diagn Invest; 2014 Jan; 26(1):104-12. PubMed ID: 24398905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease.
    Heilmann RM; Otoni CC; Jergens AE; Grützner N; Suchodolski JS; Steiner JM
    Vet Immunol Immunopathol; 2014 Oct; 161(3-4):184-92. PubMed ID: 25183017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal phagocyte-specific S100A12 for diagnosing necrotizing enterocolitis.
    Däbritz J; Jenke A; Wirth S; Foell D
    J Pediatr; 2012 Dec; 161(6):1059-64. PubMed ID: 22796048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysregulation of gastrointestinal RAGE (receptor for advanced glycation end products) expression in dogs with chronic inflammatory enteropathy.
    Cabrera-García AI; Protschka M; Alber G; Kather S; Dengler F; Müller U; Steiner JM; Heilmann RM
    Vet Immunol Immunopathol; 2021 Apr; 234():110216. PubMed ID: 33636544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
    Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
    Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.
    Kopylov U; Rosenfeld G; Bressler B; Seidman E
    Inflamm Bowel Dis; 2014 Apr; 20(4):742-56. PubMed ID: 24562174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoanalytical characteristics of fecal calprotectin.
    Desbène C; Gaillard O; Kapel N
    Ann Biol Clin (Paris); 2016 Dec; 74(6):725-734. PubMed ID: 27848924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.